← Back to Screener
RenovoRx, Inc. Common Stock (RNXT)
Price$0.87
Value ScoreD
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-12.87%
Price vs S&P 500 (4W)0.98%
VGM Score60.62
Market Capitalization$39.29M
All Metrics
Book Value / Share (Quarterly)$0.25
P/TBV (Annual)1.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)-4.36%
Gross Margin (TTM)78.71%
Net Profit Margin (TTM)-823.98%
EPS (TTM)$-0.33
10-Day Avg Trading Volume0.38M
EPS Excl Extra (TTM)$-0.33
EPS (Annual)$-0.32
ROI (Annual)-205.98%
Gross Margin (Annual)70.88%
Cash / Share (Quarterly)$0.27
Revenue Growth QoQ (YoY)185.79%
ROA (Last FY)-137.96%
EBITD / Share (TTM)$-0.35
ROE (5Y Avg)-173.15%
Operating Margin (TTM)-864.27%
Cash Flow / Share (Annual)$-0.30
P/B Ratio3.49x
P/B Ratio (Quarterly)4.04x
Net Income / Employee (Annual)$-656,900
EV / Revenue (TTM)18.08x
Net Interest Coverage (TTM)-6.61x
ROA (TTM)-104.62%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)4.02x
Quick Ratio (Quarterly)6.69x
3-Month Avg Trading Volume0.33M
52-Week Price Return-37.71%
Revenue / Employee (TTM)$87,600
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)34.98x
Asset Turnover (Annual)0.14x
52-Week High$1.45
EPS Excl Extra (Annual)$-0.32
26-Week Price Return-4.95%
Quick Ratio (Annual)3.76x
13-Week Price Return3.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.15x
Enterprise Value$26.92M
Asset Turnover (TTM)0.13x
Revenue / Employee (Annual)$66,100
Pretax Margin (Annual)-994.48%
Cash / Share (Annual)$0.19
3-Month Return Std Dev72.19%
Net Income / Employee (TTM)$-721,700
ROE (Last FY)-205.98%
Net Interest Coverage (Annual)-3.73x
EPS Basic Excl Extra (Annual)$-0.32
Receivables Turnover (TTM)5.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.33
ROI (TTM)-138.61%
P/S Ratio (TTM)26.38x
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.68
Price vs S&P 500 (52W)-62.08%
Year-to-Date Return3.80%
5-Day Price Return-5.29%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-223.86%
Net Profit Margin (Annual)-994.48%
Month-to-Date Return-4.11%
EBITD / Share (Annual)$-0.35
Operating Margin (Annual)-1113.98%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-173.15%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.33
P/TBV (Quarterly)1205.88x
P/B Ratio (Annual)5.68x
Pretax Margin (TTM)-823.98%
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)-4.51%
Beta0.94x
Revenue / Share (TTM)$0.04
ROE (TTM)-138.61%
52-Week Low$0.70
vGradeD
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.09est. -0.08
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNXTRenovoRx, Inc. Common Stock | D | A | B | $0.87 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination cancer therapies. Its proprietary Trans-Arterial Micro-Perfusion platform delivers therapeutics directly to tumors to potentially enhance efficacy while reducing toxicities compared to systemic intravenous therapy.